Onco Wiki / Indication

Colorectal carcinoma (CRC) · line 1 · FOLFOX (mFOLFOX6)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy1
Trackaggressive
Linked regimenREG-FOLFOX
IDIND-CRC-OLIGOMET-LIVER-LIMITED
TypeIndication
Statusreviewed 2026-05-08 | pending_clinical_signoff | actionability review required
DiseasesDIS-CRC
SourcesSRC-ESMO-COLON-2024 SRC-ESMO-CRC-2024 SRC-NCCN-COLON-2025

Notes

CRC liver-limited oligometastatic perioperative track per NCCN Colon v3.2025 + ESMO CRC 2024 + EORTC 40983 (Nordlinger Lancet 2008) framework. Confidence: moderate; nccn_category 2A; recommendation conditional given EORTC 40983 PFS-positive but OS-neutral primary RCT result. Re-grade to NCCN 2A high-confidence pending future RCT or ingestion of EORTC 40983 + Fong nomogram cohort sources (D2 follow-up). §17 phases: NOT populated for v0.1 (planning doc gi2_wave §4.5 recommendation 2 + §17 ratification 2026-05-07; mirrors GI-2 C5 IND-GASTRIC-OLIGOMET-SYSTEMIC-PLUS-LOCAL precedent). Local-therapy entities (hepatectomy Surgery, RFA / SBRT RadiationCourse) for CRC liver oligomet are future Phase C extensions. Sequence (induction FOLFOX → restaging → hepatic resection → adjuvant FOLFOX, total ~12 cycles perioperative) described in description / rationale / do_not_do text only. recommended_regimen: REG-FOLFOX (perioperative FOLFOX backbone per EORTC 40983; bevacizumab withheld perioperatively, distinct from REG-FOLFOX-BEV used in metastatic-only setting). Algorithm wiring deferred — algo_crc_metastatic_1l (if present) does not yet have an oligomet branch. D2 follow-up: extend algorithm wi...

Used By

Algorithms

Red flag